Trials / No Longer Available
No Longer AvailableNCT04869501
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
Expanded Access Protocol for an Intermediate Size Population-use of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- I-Mab Biopharma US Limited · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TJ004309 | Antibody to CD73 |
| DRUG | Atezolizumab | Humanized monoclonal antibody to PD-L1 |
Timeline
- First posted
- 2021-05-03
- Last updated
- 2023-04-28
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04869501. Inclusion in this directory is not an endorsement.